Počet záznamov: 1
tikagrelor
SYS d000077486 LBL 00000cy--a2200181n--4500 005 20250606222648.9 008 190101|-|anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D03.633.100.759.590.138.806 065 $a D13.570.583.138.806 065 $a D13.570.800.096.815 066 $a 01 $c 03 150 $a tikagrelor $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Brilinta $2 slo 450 $w v $a Brilique $2 slo 450 $w v $a ticagrelor $2 slo 550 $7 sllk_us_auth*d010975 $Y Platelet Aggregation Inhibitors $w P $a inhibítory agregácie trombocytov 550 $7 sllk_us_auth*d058921 $Y Purinergic P2Y Receptor Antagonists $w P $a antagonisty purinergných receptorov P2Y 665 $a 2019 (2005) $2 eng 680 9-
$i An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION. $2 eng 750 $a Ticagrelor $2 eng 980 $x M
Počet záznamov: 1